Tiziana Life Sciences plc: Publication of Research Note
Tiziana Life Sciences (NASDAQ: TLSA) has announced a new analyst research note published by H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tiziana Life Sciences (NASDAQ: TLSA) has announced a new analyst research note published by H.C. Wainwright & Co., available on their website. The company focuses on developing novel therapies for oncology, inflammation, and infectious diseases. Tiziana is advancing its pipeline, including phase 2 studies for foralumab, a human anti-CD3 monoclonal antibody targeting Crohn’s Disease and multiple sclerosis. They are also accelerating development of an anti-IL6R monoclonal antibody aimed at treating IL6-induced inflammation, particularly in COVID-19 patients.
Positive
- Initiating phase 2 studies for foralumab targeting Crohn's Disease and multiple sclerosis.
- Foralumab is the only fully human anti-CD3 mAb in clinical development globally.
- Accelerating development of anti-IL6R mAb for COVID-19 treatment.
Negative
- None.
Details
News Market Reaction – TLSA
The recorded move for TLSA in the trading session of this news was -7.89%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Company’s website at https://ir.tizianalifesciences.com/static-files/0bae55ef-6589-43f2-a4bd-65be16b3dce1
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn’s Disease and nasally administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
| For further enquiries: | |
| United Kingdom: | |
| Tiziana Life Sciences plc | |
| Gabriele Cerrone, Chairman and founder | +44 (0)20 7495 2379 |
| Cairn Financial Advisers LLP (Nominated adviser) | |
| Liam Murray / Jo Turner | +44 (0)20 7213 0880 |
| Optiva Securities Limited (Broker) | |
| Robert Emmet | +44 (0)20 3981 4173 |
| United States: | |
| Investors | |
| Dave Gentry | |
| RedChip Companies Inc. | |
| 001 407 – 491 – 4498 | |
| Dave@redchip.com | |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.